Dermatology Practice EBITDA Valuation Multiples: What Buyers Are Paying in 2024
Independent dermatology practices are trading at 4x–7x EBITDA. Cosmetic revenue mix, provider depth, and payer diversification are the key valuation levers.
Dermatology practices are among the most acquisitive specialties in lower middle market healthcare M&A, driven by private equity roll-up demand and favorable demographics. Practices with $1M–$5M revenue typically trade at 4x–7x EBITDA, with premium multiples reserved for those combining strong cosmetic cash-pay revenue with multi-provider clinical teams and diversified payer contracts.
Dermatology Practice EBITDA Multiple Ranges by Tier
| Business Tier | EBITDA Range | Multiple Range | Notes |
|---|---|---|---|
| Solo Physician, Medical-Only | $300K–$600K | 4x–5x | High key-person risk with single MD driving 80%+ of revenue. Limited cosmetic mix. Often structured with SBA financing and seller transition period. |
| Small Group, Mixed Revenue | $600K–$1M | 5x–6x | 2+ providers with some cosmetic revenue. Moderate payer diversification. Attractive to physician entrepreneurs and smaller PE platforms. |
| Established Multi-Provider Practice | $1M–$2M | 6x–7x | Strong cosmetic and medical revenue split, recurring patient base, modern EMR. Prime target for dermatology roll-up platforms with equity rollover structures. |
| Platform-Ready Group Practice | $2M+ | 7x+ | Multiple locations or high-volume single site with PA/NP leverage. Scalable infrastructure and clean malpractice history command top-of-range premiums. |
What Drives Dermatology Practice Multiples
Cosmetic Revenue Mix
High Positive impactBotox, fillers, and laser services carry 60–70% margins and are cash-pay, significantly increasing EBITDA quality and buyer demand compared to insurance-dependent medical revenue.
Provider Depth and Key-Person Risk
High Positive or Negative impactPractices with 2+ licensed dermatologists or strong PA/NP support reduce key-person dependency, a critical concern for buyers underwriting physician retention post-acquisition.
Payer Mix and Reimbursement Stability
Moderate impactPractices with less than 40% Medicare concentration and strong commercial contracts command higher multiples due to reduced exposure to reimbursement rate compression.
Malpractice History and Compliance
High Negative if Poor impactUnresolved malpractice claims, state medical board actions, or gaps in tail coverage are deal-killers that suppress multiples or derail transactions entirely.
EMR Infrastructure and Revenue Cycle Quality
Moderate Positive impactModern practice management software with clean billing and collections history reduces integration costs for acquirers and supports higher confidence in normalized EBITDA.
Recent Market Trends
PE-backed dermatology platforms continue aggressive roll-up activity, pushing multiples toward the higher end of the 6x–7x range for platform-quality practices. Cosmetic revenue streams, particularly injectables, are commanding premium valuations. MSO structures are increasingly standard to navigate corporate practice of medicine compliance across states.
Sample Dermatology Practice Transactions
Solo dermatologist with growing Botox/filler program and 1 PA in suburban Southeast market. Clean malpractice history, 3-year lease renewal secured.
$550K
EBITDA
5.2x
Multiple
$2.86M
Price
Two-physician group with 35% cosmetic revenue, diversified commercial payer mix, and modern EMR in mid-size Midwest metro. Minimal Medicare dependency.
$980K
EBITDA
6.1x
Multiple
$5.98M
Price
Three-provider practice with two locations, strong aesthetic program, and PA leverage. Targeted by regional dermatology roll-up platform with equity rollover.
$1.8M
EBITDA
6.8x
Multiple
$12.24M
Price
EBITDA Valuation Estimator
Get your Dermatology Practice business value range instantly
Industry: Dermatology Practice · Multiples based on 5x–6x (Small Group, Mixed Revenue)
Powered by Deal Flow OS
dealflow-os.com · Free M&A tools for every stage of the deal
Frequently Asked Questions
What EBITDA multiple should I expect when selling my dermatology practice?
Most independent dermatology practices sell at 4x–7x EBITDA. Practices with strong cosmetic revenue, multiple providers, and clean compliance records achieve the upper range of 6x–7x.
Does cosmetic revenue increase my dermatology practice valuation?
Yes significantly. Cash-pay cosmetic services like Botox and laser treatments carry higher margins than insurance-reimbursed procedures, improving EBITDA quality and attracting premium multiples from PE buyers.
Can I use an SBA loan to buy a dermatology practice?
Yes. Dermatology practices are SBA 7(a) eligible. Buyers commonly combine SBA financing with a seller note covering 10–15% of purchase price and a 12–24 month seller transition period.
How does physician retention risk affect dermatology practice multiples?
It's one of the top valuation concerns. Practices where one physician drives 80%+ of revenue face multiple compression and heavy earnout structures until buyer confidence in retention is established.
More Dermatology Practice Guides
Find Dermatology Practice businesses at the right price
DealFlow OS surfaces acquisition targets with seller signals and outreach angles. Free to join.
Start finding deals — freeNo credit card required